Alzamend Neuro, Inc. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ALZN002 (autologous DCs pulsed with E22W mutant peptide).ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.	Alzheimer	Phase 1/2		United States	À vérifier
ALZN002 (autologous DCs pulsed with E22W mutant peptide).ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.	Alzheimer	Phase 1/2		United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
ALZN002 (autologous DCs pulsed with E22W mutant peptide).	Alzheimer	Phase 1/2	NCT05834296	Study in Subjects With Mild-to-Moderate Alzheimer's Dementia	ACTIVE_NOT_RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
ALZN002 (autologous DCs pulsed with E22W mutant peptide).		Fimbriated Porphyromonas gingivalis is more efficient than fimbria-deficient P. gingivalis in entering human dendritic cells in vitro and induces an inflammatory Th1 effector response.	Infection and immunity
ALZN002 (autologous DCs pulsed with E22W mutant peptide).		An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.	Molecular cancer therapeutics
ALZN002 (autologous DCs pulsed with E22W mutant peptide).		Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine